Novartis' bid to complete its proposed acquisition of Alcon has met another hurdle after an independent Swiss corporate law expert concluded that the eye care specialist's independent director committee (IDC) must reach a recommendation before Alcon's board can make a final decision on ...
Please Login to read the full article.
